Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.75 |
| ▸ | CA2 | P00918 | 13/20 | 0.75 |
| ▸ | CA9 | Q16790 | 13/20 | 0.75 |
| ▸ | CA12 | O43570 | 6/20 | 0.75 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.64 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.63 |
| ▸ | HTR3A | P46098 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675190 | 0.92 | CA1 (0.68) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14642801 | 0.91 | CA1 (0.67) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19426705 | 0.91 | CA9 (0.71) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13219607 | 0.90 | CA1 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14032186 | 0.90 | CA9 (0.67) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13815114 | 0.90 | CA1 (0.71) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13609838 | 0.90 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12185092 | 0.89 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12608907 | 0.89 | CA9 (0.76) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12678101 | 0.89 | CA9 (0.72) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | NEKTAR THERAPEUTICS (US) | 2024-06-25 | — | — | US | disclosed |
| US-20170095565-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-9388104-B2 | Chemically modified small molecules | NEKTAR THERAPEUTICS (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150197470-A9 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140303403-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120088745-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095565-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, PLG | CA1 1388/4885CA2 2227/4885CA9 650/4885 |
| US-20120088745-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, PLG | CA1 1388/4885CA2 2227/4885CA9 650/4885 |
| US-20150197470-A9 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, PLG | CA1 1388/4885CA2 2227/4885CA9 650/4885 |
| US-20140303403-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, PLG | CA1 1388/4885CA2 2227/4885CA9 650/4885 |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | POLM, OGG1, COPE | CA1 2271/4885CA2 3596/4885CA9 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.